Contexte sectoriel
Prime Medicine Inc [PRME]
Dernière mise à jour 24 Jun 2026 @ 16:00 (Exchange is closed)
Dernier : $3.12
-3.70%
0.00
GaG Algo Score™
v1.0
Court
0.00
Moyen
-1.62 (↓)
Long
-2.08 (↓)
Ligne
Données pivot
Statistiques pivot
| Métrique | Moyenne | Médiane | Écart type |
|---|---|---|---|
| Gain % | 34.22% | 31.48% | 7.12% |
| Perte % | -31.89% | -31.29% | 10.11% |
| Durée | 22.8d | 23d | 14.5d |
| Total des pivots trouvés | 12 |
| Segments gain/perte | 11 (5 Gain / 6 Perte) |
| Dernier pivot | Bottom @ $2.71 le 2026-06-10 |
| Variation depuis le dernier pivot | $0.53 (19.56%) |
Prévision du prochain pivot Dernier : $3.12
| Prochain type prévu | Top |
| Prix prévu (moy.) | $3.64 |
| Prix prévu (médiane) | $3.56 |
| Fourchette de prix prévue (~68%) | $3.44 - $3.83 |
| Variation vers cible moyenne | $0.52 (16.58%) |
| Date prévue (moy.) | 2026-07-02 |
| Plage de dates prévue (~68%) | 2026-06-18 - 2026-07-17 |
| Base | Based on 5 historical gains (Avg: 34.22%, Median: 31.48%, StdDev: 7.12%) and duration (Avg: 22.8 days, StdDev: 14.5 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Significant fall for Prime Medicine Inc, down -3.86%.
Prime Medicine Inc (PRME) stock price dropped sharply on Tuesday after the stock fell $-0.130 (-3.86%) from the previous session on normal volume. The stock fell slightly more than the NASDAQ which was down -0.40%. A total of 2.96M stocks were traded yesterday, valued at $9.60M, 536 351 shares less than the previous day (3 500 800 shares traded). This is near the average volume for the stock at 2.79M shares traded per day.
Prime Medicine Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-10%), medium- (-10%), and long-term (-10%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Prime Medicine Inc Support & Resistance Levels
The stock is trading above the closest support level at $2.97. approximately $0.270 (8.33%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s12.97 -
Prime Medicine Inc Evaluation
- Court score: 0.00
- Moyen score: -1.62
- Long score: -2.08
Flux des initiés
GetAGraph InsiderPower
Transactions
107
Force acheteuse
112.40M
Force vendeuse
19.70M
Fiabilité
100/100
Achat / vente
5.71
Corr. hist.
-0.30
Dernier signal
Buy 2026-06-22
Director 59
Officer 38
Major holder 10
2026-06-05
Schenkein David P Director
Buy 75 000
2026-06-05
Marrazzo Jeffrey D Director
Buy 75 000
2026-06-05
Nelsen Robert Director
Buy 75 000
2026-06-05
Kelly Michael Aaron Director
Buy 75 000
2026-06-05
Foster-cheek Kaye I Director
Buy 75 000
2026-06-05
Chung Wendy Director
Buy 75 000
Contexte événementiel
Volume et dividendes
Corr. volume longue
0.17
Corr. volume courte
0.64
Positioning pressure
Short interest pressure
Short interest
17.41%
Of outstanding shares
Short float
53.15%
Of tradable float
Days to cover
11.21
Short interest divided by average volume
Squeeze probability
100.00%
+0.96% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Income profile
Dividend profile
Dernier dividende
$0.800
2019-09-10
Prochain dividende
$0
N/A
Avg. yearly yield
0.00%
Quarterly
Total paid
$3.83
15 payments
Sustainability
0
low (50.00%)
Growth potential
0
No dividend growth expected in the near future
Direction
0
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2019-09-10 | $0.800 | 2019-09-12 |
| 2019-06-14 | $0.200 | 2019-06-28 |
| 2018-12-18 | $0.213 | 2018-12-31 |
| 2018-09-14 | $0.233 | 2018-09-28 |
| 2018-06-21 | $0.146 | 2018-06-29 |
Earnings quality
Earnings history
Reported quarters
12
EPS beats
3
EPS misses
6
Avg. surprise
-5.71%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q4/2024 | 2025-03-07 | $-0.350 | $-0.370 | 5.41% | 2.18M |
| Q3/2024 | 2024-11-12 | $-0.440 | $-0.430 | -2.33% | 209 000 |
| Q2/2024 | 2024-08-08 | $-0.460 | $-0.400 | -15.00% | 37.77M |
| Q1/2024 | 2024-05-10 | $-0.440 | $-0.450 | 2.22% | 591 000 |
| Q4/2023 | 2024-03-01 | $-0.560 | $-0.480 | -16.67% | 25.69M |
| Q3/2023 | 2023-11-03 | $-0.550 | $-0.450 | -22.22% | - |
| Q2/2023 | 2023-08-07 | $-0.470 | $-0.420 | -11.90% | - |
| Q1/2023 | 2023-05-11 | $-0.440 | $-0.420 | -4.76% | - |
Analyst view
Analyst targets
Consensus
$6.00
Median
$6.00
Low
$6.00
High
$6.00
News flow
Latest company news
Market coverage
globenewswire.com Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) Jun 22, 2026 globenewswire.com Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease Jun 18, 2026 fool.com Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? Jun 15, 2026 seekingalpha.com Prime Medicine's Prime Editing Is Worth The Risk Jun 13, 2026Company releases
Company context
Company profile
Bourse :
NASDAQ
Secteur :
Healthcare
Industrie :
Biotechnology
Currency
USD
Prime Medicine Inc operates as a biotechnology firm dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology Central to their platform is the Prime Editor system which combines a unique Prime Editor proteina hybrid composed of a Cas protein and a reverse transcriptase enzymewith a specialized pegRNA molecule This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence The company founded in 2019 maintains its headquarters in Cambridge Massachusetts
Navigation